These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4161 related articles for article (PubMed ID: 24315724)

  • 1. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
    Ruff CT; Giugliano RP; Braunwald E; Hoffman EB; Deenadayalu N; Ezekowitz MD; Camm AJ; Weitz JI; Lewis BS; Parkhomenko A; Yamashita T; Antman EM
    Lancet; 2014 Mar; 383(9921):955-62. PubMed ID: 24315724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
    Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.
    Dogliotti A; Paolasso E; Giugliano RP
    Clin Cardiol; 2013 Feb; 36(2):61-7. PubMed ID: 23338902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation.
    Jia B; Lynn HS; Rong F; Zhang W
    J Cardiovasc Pharmacol; 2014 Oct; 64(4):368-74. PubMed ID: 24869601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
    Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
    Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
    Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
    Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Briceno DF; Villablanca P; Cyrille N; Massera D; Bader E; Manheimer E; Aagaard P; Ferrick K; Gross J; Kim SG; Krumerman A; Palma E; Guttenplan N; Romero J; Fisher J; Garcia M; Natale A; Di Biase L
    Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1057-64. PubMed ID: 26226997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
    Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
    Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials.
    Liew A; O'Donnell M; Douketis J
    J Thromb Haemost; 2014 Sep; 12(9):1419-24. PubMed ID: 24986568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
    Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
    Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.
    Rong F; Jia B; Huang P; Lynn HS; Zhang W
    Thromb Res; 2015 Jun; 135(6):1117-23. PubMed ID: 25891842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 209.